CCAP Crescent Capital BDC, Inc. Insider Trading

President Henry Chung buys 4,500 shares of CCAP at $11.45; 3 other insiders also bought within 14 days. Stock down -28.7% from 52-week high.

Henry Chung, President of Crescent Capital BDC, Inc., purchased 4,500 shares at $11.45, bringing his holdings from 16,222 shares to 20,722 shares (a +27.7% increase in his position). The transaction occurs amid a cluster of buying activity: 3 other insiders also purchased shares within the past 14 days. The current price of $11.44 is -28.7% from the 52-week high of $16.04, representing significant recent decline. The company reported net income of $-15,513,000.00, adding complexity to the valuation context. This filing signals sustained insider accumulation across multiple executives during a period of depressed share prices relative to recent highs.

CCAP CEO Jason Breaux buys 5,000 shares at $11.19; cluster of 2 other insider buys in past 14 days as stock down 28.7% YTD.

Jason Breaux, CEO of Crescent Capital BDC, purchased 5,000 shares at $11.19 on 2026-05-20, increasing his holdings from 47,636 shares to 52,636 shares. This purchase occurs within a cluster pattern—2 other insiders also bought within the past 14 days—while the stock has declined 28.7% from its 52-week high of $16.04 and dropped 15.3% over the past 30 days. The CEO's purchase at depressed price levels, coordinated with concurrent insider buying activity, occurs despite the company reporting negative net income of $-15,513,000.00, a metric that contexualizes the stock's recent weakness. The cluster buy pattern and CEO participation at a significantly lower valuation point warrant attention to whether this reflects insider assessment of value or a response to operational headwinds.

CFO Lombard Gerhard buys 1,000 shares of CCAP at $11.12; stock down 30.7% from 52-week high, trading -16.4% in 30 days.

Lombard Gerhard, Chief Financial Officer of Crescent Capital BDC, purchased 1,000 shares at $11.12 on 2026-05-18, increasing his holdings from 36,373 to 37,373 shares. The transaction occurred amid notable weakness in CCAP: the stock is trading at $11.37, down 30.7% from its 52-week high of $16.40 and down 16.4% over the past 30 days. Gerhard's prior buy at this ticker on 2025-11-17 posted positive 30d and 90d returns, marking 1 of 1 prior buys well-timed at the 90-day mark. However, the current purchase takes place as the company reports a net loss of $-15,513,000.00 and carries a P/E of 27.73, suggesting the recent price decline has not yet fully reflected fundamental weakness. The modest size of this transaction relative to his existing holdings (2.7% increase) and the deteriorating short-term price momentum warrant closer examination of the underlying motivation.

Director Strandberg buys 85,000 CCAP shares at $11.28; holdings rise to 201.1K shares (+73.2%)

Steven F. Strandberg, a director at Crescent Capital BDC, purchased 85,000 shares at $11.28 on 2026-05-19, increasing his holdings from 116.1K to 201.1K shares (a 73.2% increase in position size). The transaction totaled $958.5K. The timing occurs against a backdrop of significant stock weakness: the current price of $11.37 is -30.7% from the 52-week high of $16.40 and down -16.4% over the prior 30 days. The company is reporting net losses ($-15.5M) rather than profits, which adds context to the valuation at which this purchase occurred. This discrete purchase by a director warrants monitoring as a data point in the broader market and fundamental environment for the company.